Insider Selling: Sera Prognostics (NASDAQ:SERA) CFO Sells 5,263 Shares of Stock

Key Points

• Austin Aerts, CFO of Sera Prognostics, sold 5,263 shares of the company's stock for approximately $16,578, reducing his ownership by 1.81%.
• Sera Prognostics' stock price decreased by 2.2% on the same day, closing at $3.10, with a market cap of $116.78 million.
• Wall Street analysts downgraded Sera Prognostics from a "hold" to a "sell" rating, indicating a bearish outlook on the company's performance.

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CFO Austin Aerts sold 5,263 shares of the stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $3.15, for a total value of $16,578.45. Following the transaction, the chief financial officer directly owned 285,585 shares of the company's stock, valued at approximately $899,592.75. This trade represents a 1.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Austin Aerts also recently made the following trade(s):

• On Thursday, September 11th, Austin Aerts sold 915 shares of Sera Prognostics stock. The shares were sold at an average price of $3.13, for a total value of $2,863.95.

Sera Prognostics Stock Performance

NASDAQ SERA traded up $0.03 on Friday, hitting $3.10. 44,671 shares of the stock traded hands, compared to its average volume of 105,485. The business's fifty day moving average is $2.81 and its two-hundred day moving average is $2.85. Sera Prognostics, Inc. has a 12 month low of $1.37 and a 12 month high of $9.13. The firm has a market capitalization of $116.78 million, a price-to-earnings ratio of -3.65 and a beta of 1.00.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%.The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

A number of institutional investors and hedge funds have recently made changes to their positions in SERA. BNP Paribas Financial Markets purchased a new stake in shares of Sera Prognostics in the fourth quarter worth $28,000. Abel Hall LLC purchased a new stake in shares of Sera Prognostics in the second quarter worth $31,000. Wagner Wealth Management LLC purchased a new stake in shares of Sera Prognostics in the second quarter worth $34,000. Riverview Capital Advisers LLC purchased a new stake in shares of Sera Prognostics in the second quarter worth $35,000. Finally, XTX Topco Ltd purchased a new stake in shares of Sera Prognostics in the first quarter worth $39,000. Hedge funds and other institutional investors own 54.64% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen lowered Sera Prognostics from a "hold" rating to a "sell" rating in a report on Saturday, August 9th.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.